Chemfab Alkalis Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 8:13 am

Competitors of Chemfab Alkalis Ltd

All Competitor Stocks of Chemfab Alkalis Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:45 pm

Below is a detailed analysis of the quarterly data for Chemfab Alkalis Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 87.58 Cr.. The value appears to be declining and may need further review. It has decreased from 87.85 Cr. (Mar 2025) to 87.58 Cr., marking a decrease of 0.27 Cr..
• For Expenses, as of Jun 2025, the value is 74.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.16 Cr. (Mar 2025) to 74.16 Cr., marking an increase of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 13.42 Cr.. The value appears to be declining and may need further review. It has decreased from 15.69 Cr. (Mar 2025) to 13.42 Cr., marking a decrease of 2.27 Cr..
• For OPM %, as of Jun 2025, the value is 15.32%. The value appears to be declining and may need further review. It has decreased from 17.86% (Mar 2025) to 15.32%, marking a decrease of 2.54%.
• For Other Income, as of Jun 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 1.27 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 0.21 Cr..
• For Interest, as of Jun 2025, the value is 1.56 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.56 Cr..
• For Depreciation, as of Jun 2025, the value is 5.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.64 Cr. (Mar 2025) to 5.38 Cr., marking a decrease of 4.26 Cr..
• For Profit before tax, as of Jun 2025, the value is 7.54 Cr.. The value appears strong and on an upward trend. It has increased from 5.76 Cr. (Mar 2025) to 7.54 Cr., marking an increase of 1.78 Cr..
• For Tax %, as of Jun 2025, the value is 28.38%. The value appears to be improving (decreasing) as expected. It has decreased from 31.77% (Mar 2025) to 28.38%, marking a decrease of 3.39%.
• For Net Profit, as of Jun 2025, the value is 5.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.93 Cr. (Mar 2025) to 5.39 Cr., marking an increase of 1.46 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.75. The value appears strong and on an upward trend. It has increased from 2.74 (Mar 2025) to 3.75, marking an increase of 1.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:34 am

Growth

Last Updated: September 5, 2025, 1:55 am

Balance Sheet

Last Updated: November 9, 2025, 1:50 pm

Below is a detailed analysis of the balance sheet data for Chemfab Alkalis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
• For Reserves, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 393.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 6.00 Cr..
• For Borrowings, as of Sep 2025, the value is 107.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 84.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 23.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 85.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 54.00 Cr. (Mar 2025) to 85.00 Cr., marking an increase of 31.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 605.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 546.00 Cr. (Mar 2025) to 605.00 Cr., marking an increase of 59.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 249.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 249.00 Cr..
• For CWIP, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 49.00 Cr..
• For Investments, as of Sep 2025, the value is 149.00 Cr.. The value appears to be declining and may need further review. It has decreased from 164.00 Cr. (Mar 2025) to 149.00 Cr., marking a decrease of 15.00 Cr..
• For Other Assets, as of Sep 2025, the value is 146.00 Cr.. The value appears strong and on an upward trend. It has increased from 121.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 25.00 Cr..
• For Total Assets, as of Sep 2025, the value is 605.00 Cr.. The value appears strong and on an upward trend. It has increased from 546.00 Cr. (Mar 2025) to 605.00 Cr., marking an increase of 59.00 Cr..

Notably, the Reserves (399.00 Cr.) exceed the Borrowings (107.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Chemfab Alkalis Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -4.86. This value is below the healthy minimum of 5. It has decreased from 18.53 (Mar 24) to -4.86, marking a decrease of 23.39.
• For Diluted EPS (Rs.), as of Mar 25, the value is -4.84. This value is below the healthy minimum of 5. It has decreased from 18.34 (Mar 24) to -4.84, marking a decrease of 23.18.
• For Cash EPS (Rs.), as of Mar 25, the value is 20.46. This value is within the healthy range. It has decreased from 34.21 (Mar 24) to 20.46, marking a decrease of 13.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 232.79. It has increased from 230.06 (Mar 24) to 232.79, marking an increase of 2.73.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 35.39. This value is within the healthy range. It has decreased from 43.89 (Mar 24) to 35.39, marking a decrease of 8.50.
• For PBIT / Share (Rs.), as of Mar 25, the value is 10.10. This value is within the healthy range. It has decreased from 28.18 (Mar 24) to 10.10, marking a decrease of 18.08.
• For PBT / Share (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0. It has decreased from 27.52 (Mar 24) to -0.21, marking a decrease of 27.73.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
• For PBDIT Margin (%), as of Mar 25, the value is 15.20. This value is within the healthy range. It has decreased from 19.07 (Mar 24) to 15.20, marking a decrease of 3.87.
• For PBIT Margin (%), as of Mar 25, the value is 4.33. This value is below the healthy minimum of 10. It has decreased from 12.24 (Mar 24) to 4.33, marking a decrease of 7.91.
• For PBT Margin (%), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 10. It has decreased from 11.96 (Mar 24) to -0.09, marking a decrease of 12.05.
• For Net Profit Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 5. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 8. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
• For Return on Networth / Equity (%), as of Mar 25, the value is -1.82. This value is below the healthy minimum of 15. It has decreased from 6.80 (Mar 24) to -1.82, marking a decrease of 8.62.
• For Return on Capital Employeed (%), as of Mar 25, the value is 3.22. This value is below the healthy minimum of 10. It has decreased from 9.81 (Mar 24) to 3.22, marking a decrease of 6.59.
• For Return On Assets (%), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 5. It has decreased from 5.26 (Mar 24) to -1.33, marking a decrease of 6.59.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.16, marking an increase of 0.12.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.21, marking an increase of 0.17.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.71 (Mar 24) to 0.65, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.65, marking an increase of 0.56.
• For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.28, marking an increase of 0.36.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.48. This value exceeds the healthy maximum of 8. It has increased from 4.47 (Mar 24) to 15.48, marking an increase of 11.01.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -25.71. This value is below the healthy minimum of 20. It has decreased from 6.73 (Mar 24) to -25.71, marking a decrease of 32.44.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 20. It has increased from 3.64 (Mar 24) to 6.07, marking an increase of 2.43.
• For Earning Retention Ratio (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.27 (Mar 24) to 125.71, marking an increase of 32.44.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.93. This value exceeds the healthy maximum of 70. It has decreased from 96.36 (Mar 24) to 93.93, marking a decrease of 2.43.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 66.27 (Mar 24) to 10.32, marking a decrease of 55.95.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 3. It has decreased from 28.94 (Mar 24) to 1.60, marking a decrease of 27.34.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,091.47. It has increased from 916.08 (Mar 24) to 1,091.47, marking an increase of 175.39.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.80 (Mar 24) to 3.26, marking an increase of 0.46.
• For EV / EBITDA (X), as of Mar 25, the value is 21.47. This value exceeds the healthy maximum of 15. It has increased from 14.67 (Mar 24) to 21.47, marking an increase of 6.80.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
• For Retention Ratios (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 125.71, marking an increase of 32.45.
• For Price / BV (X), as of Mar 25, the value is 2.67. This value is within the healthy range. It has increased from 2.38 (Mar 24) to 2.67, marking an increase of 0.29.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
• For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness